Investment details
Entry
Staff
25Location
SwitzerlandOur goal with ImmunOs is to develop novel therapeutics based on our proprietary human leukocyte antigen (HLA)-based platform to create a new class of biologic therapeutics for the treatment of cancer and autoimmune diseases to improve the lives of patients with serious diseases.
Sean R. Smith
CEO
Partnership Gimv Partnership Gimv Partnership Gimv
Partnership Gimv
ImmunOs' approach to new cancer drugs is based on insights into how the human body controls the immune system and translates these into new treatment approaches for the benefit of patients. This epitomises the mission of Gimv's life sciences platform: to build leading companies that have a lasting impact on patients and society.
Deal Team
News News News